List view / Grid view

Yannis Morel (Innate Pharma)

 

article

NK cell immunotherapy: what’s next in clinical development?

In this interview, Innate Pharma’s Yannis Morel, Executive Vice President…

12 December 2023 | By

In this interview, Innate Pharma’s Yannis Morel, Executive Vice President of product portfolio strategy and business development, delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications, and shares key data from the company’s ongoing and recent clinical trials.